{"id":94436,"topic":"peptides","source":"生物通","title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","url_hash":"9c3708007e6312876ac1ec8fc0dc47482e4a6a39","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMibkFVX3lxTE9iRFhpUHprVzRBLVY1WTZheHREUTc2WFYzREtUX3QwSk1JekxoX3ZrYmR5eEJ6RDZGOVpEUzFQT0hqalJnQTVtOGRtYWRJU3VrWXZhTGlJbmFlQjdKOFQ5cUk3NFdITFNqd0Q5bm13?oc=5\" target=\"_blank\">功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物通</font>","content":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. EFSA (Eu)\nÃÀ¹úÎÞ¹¦ÄÜÐÔʳƷÀà±ð£¬GRASΪ°²È«È϶¨£¬½¡¿µÉù³ÆÐè petition£¬²¹³ä¼Á¿É×÷½á¹¹/¹¦ÄÜÉù³Æ£»Å·ÃËRegulation (EC) No. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","image_url":null,"lang":"zh","published_at":"2026-10-01T23:59:03+00:00","fetched_at":"2026-10-02T01:15:23+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 6290 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":6290,"summary_length":6172,"usable_text_length":6290,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":6290,"summary_length":6172}},"news_item":{"id":94436,"canonical_url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","source_url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","source_name":"生物通","author":null,"published_at":"2026-10-01T23:59:03+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMibkFVX3lxTE9iRFhpUHprVzRBLVY1WTZheHREUTc2WFYzREtUX3QwSk1JekxoX3ZrYmR5eEJ6RDZGOVpEUzFQT0hqalJnQTVtOGRtYWRJU3VrWXZhTGlJbmFlQjdKOFQ5cUk3NFdITFNqd0Q5bm13?oc=5\" target=\"_blank\">功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物通</font>","full_text":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. EFSA (Eu)\nÃÀ¹úÎÞ¹¦ÄÜÐÔʳƷÀà±ð£¬GRASΪ°²È«È϶¨£¬½¡¿µÉù³ÆÐè petition£¬²¹³ä¼Á¿É×÷½á¹¹/¹¦ÄÜÉù³Æ£»Å·ÃËRegulation (EC) No. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","excerpt":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 6290 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 6290 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":6290,"summary_length":6172,"usable_text_length":6290,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":6290,"summary_length":6172}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","summary":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","source":"生物通","date":"2026-10-01T23:59:03+00:00","content":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. EFSA (Eu)\nÃÀ¹úÎÞ¹¦ÄÜÐÔʳƷÀà±ð£¬GRASΪ°²È«È϶¨£¬½¡¿µÉù³ÆÐè petition£¬²¹³ä¼Á¿É×÷½á¹¹/¹¦ÄÜÉù³Æ£»Å·ÃËRegulation (EC) No. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 6290 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 6290 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":6290,"summary_length":6172,"usable_text_length":6290,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":6290,"summary_length":6172}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/94436","export_markdown":"/api/items/94436/export?format=markdown","export_json":"/api/items/94436/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm"},"formats":{"full":{"id":94436,"title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","source":"生物通","author":null,"published_at":"2026-10-01T23:59:03+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","full_text":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. EFSA (Eu)\nÃÀ¹úÎÞ¹¦ÄÜÐÔʳƷÀà±ð£¬GRASΪ°²È«È϶¨£¬½¡¿µÉù³ÆÐè petition£¬²¹³ä¼Á¿É×÷½á¹¹/¹¦ÄÜÉù³Æ£»Å·ÃËRegulation (EC) No. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 6290 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 6290 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":6290,"summary_length":6172,"usable_text_length":6290,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":6290,"summary_length":6172}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 6290 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":6290,"summary_length":6172,"usable_text_length":6290,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":6290,"summary_length":6172}},"actions":{"read":"/item/94436","export_markdown":"/api/items/94436/export?format=markdown","export_json":"/api/items/94436/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm"}},"digest":{"id":94436,"title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","source":"生物通","topic":"peptides","published_at":"2026-10-01T23:59:03+00:00","excerpt":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects ¡¡¡¡…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 6290 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","subtitle":"生物通 · 2026-10-01","summary":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects ¡¡¡¡…","badges":["quality:high"],"links":{"read":"/item/94436","original":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm"},"quality_warning":null},"export":{"title":"功能性食品中生物活性肽（BAPs）：从生产与验证到商业化、监管壁垒及未来前景 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","summary":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","source":"生物通","date":"2026-10-01T23:59:03+00:00","content":"¡¶JOURNAL OF FOOD SCIENCE¡·£ºBioactive Peptides in Functional Foods: From Production and Validation to Commercialization, Regulatory Hurdles, and Future Prospects\n        \n        ¡¡¡¡\nÉúÎï»îÐÔëÄ£¨BAPs£©±íÏÖ³ö¹ã·ºµÄ½¡¿µ´Ù½ø×÷Óã¬Ê¹Æä³ÉΪ¹¦ÄÜÐÔʳƷÊг¡µÄ¹Ø¼ü³É·Ö¡£±¾×ÛÊö¶ÔBAPsµÄÕûÌå¸ñ¾Ö½øÐÐÁËÈ«ÃæÆÀ¹À£¬º¸Ç´Ó·¢ÏÖºÍÉú²úµ½ÉÌÒµ»¯¼°¼à¹Ü¡£ÎÄÕÂÅúÅÐÐÔ·ÖÎöÁË´«Í³ÓëÐÂÐËÉú²ú¼¼Êõ£¬Öصã½éÉÜÁËø½â¡¢Î¢ÉúÎï·¢½ÍÒÔ¼°¸ßѹºÍ³¬Éù¸¨ÖúÌáÈ¡µÈÎïÀí¼Ó¹¤·½·¨µÄ½øÕ¹¡£ÎÄÕ¿¼²ìÁ˶à²ãÑéÖ¤Á÷³Ì£¬°üÀ¨¼ÆËã»úÄ£Ä⣨in silico£©Ô¤²â¡¢ÌåÍâɸѡºÍÌåÄÚÄ£ÐÍ£¬½ÒʾÁ˳õ²½ÉúÎï»îÐÔÊý¾ÝÓë¿ÉÖ¤Ã÷µÄÁÙ´²ÁÆЧ֮¼äµÄÏÔÖøÍѽڣ¬¶øÕâÊǼà¹Üʧ°ÜµÄÒ»¸öÖ÷ÒªÔÒò¡£ÉÌÒµ»¯Êܵ½¼¼ÊõÌôÕ½µÄ×è°£¬°üÀ¨ÉúÎïÀûÓöȲ賦µÀ²»Îȶ¨ÐԺͲ»Á¼¸Ð¹ÙÊôÐÔ£¬ÕâЩÎÊÌâÕýͨ¹ýÄÉÃ×°ü·âµÈ´´ÐÂÖƼÁ²ßÂÔ¼ÓÒÔÓ¦¶Ô¡£¶ÔÈ«Çò¼à¹Ü¿ò¼ÜµÄ±È½Ï·ÖÎö£¬ÓÈÆäÊÇÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ºÍÅ·ÃËʳƷ°²È«¾Ö£¨EFSA£©µÄ²»Í¬×ö·¨£¬Í¹ÏÔÁË֤ʵ½¡¿µÉù³ÆµÄÕÏ°£¬²¢ÆÕ±éÒªÇó¿ªÕ¹ÑϸñµÄÈËÌåÁÙ´²ÊÔÑé¡£×îºó£¬ÎÄÕÂ̽ÌÖÁËδÀ´Ç°¾°£¬Ê¶±ðÁ˹ؼüÑо¿È±¿Ú£¬²¢Ç¿µ÷ÁËÈ˹¤ÖÇÄÜ£¨AI£©Çý¶¯µÄëÄÉè¼ÆºÍͨ¹ýÓªÑø»ùÒò×éѧ£¨nutrigenomics£©ÊµÏÖ¸öÐÔ»¯ÓªÑøµÄ±ä¸ïDZÁ¦£¬ÒÔÊÍ·ÅBAPsµÄÈ«²¿Ç±Á¦¡£±¾×ÛÊö½øÒ»²½½«ëĽṹÓë¾ÅÖÖÖ÷ÒªÉúÎï»îÐÔÁªÏµÆðÀ´£¬ÅúÅÐÐԱȽÏÁËÏȽøµÝËÍϵͳºÍÖÆÔì·Å´ó£¬²¢½«¼à¹Ü·ÖÎöÀ©Õ¹µ½Ö÷ÒªÑÇÌ«Êг¡¡£\n1 Introduction\nÉúÎï»îÐÔëÄ£¨BAPs£©ÊÇÇ×±¾µ°°×ÖÐÎÞ»îÐÔ¡¢Êͷźó²úÉúÉúÀíЧӦµÄ2¨C20¸ö°±»ùËᣨAA£©Æ¬¶Î£¬À´Ô´º¸ÇÈé¡¢Èâ¡¢µ°¡¢´ó¶¹¡¢¹ÈÎï¡¢¶¹À༰ÓãÔå¡£Æä½á¹¹¨C»îÐÔ¹ØϵÓÉAA×é³É¡¢ÐòÁС¢µçºÉ¡¢ÊèË®ÐÔºÍÁ½Ç×ÐԵȾö¶¨£¬¹¦ÄÜ°üÀ¨¿¹¸ßѪѹ¡¢¿¹Ñõ»¯¡¢¿¹¾ú¡¢ÃâÒßµ÷½Ú¡¢¿¹ÌÇÄò²¡µÈ¡£ValorizationÍƶ¯¸±²úÎïת»¯Îª¸ßÖµÅäÁÏ¡£±¾×ÛÊöÆÀ¹À´ÓÉú²ú¡¢ÑéÖ¤µ½ÉÌÒµ»¯¡¢¼à¹ÜºÍÇ°¾°¡£\n2 The Discovery and Validation of BAPs: A Critical Assessment\n2.1 Generation of Bioactive Peptides\n2.1.1 Conventional Approaches\nø½â¸ßÌØÒ졢κ͡¢Ê³Æ·¼¶£¬µ«Ã¸¹ó¡¢²úÂÊ¿ÉÄܵͣ»Î¢ÉúÎï·¢½Í³É±¾µÍµ«¿ØÖƲ»¯Ñ§ºÏ³ÉºÍÖØ×é±í´ï¿É¾«È·¿ØÖÆÐòÁУ¬ÊʺϸßÖµ¶ÌëÄ£¬µ«³É±¾¡¢´¿»¯ºÍGMP¸ºµ£¸ß¡£\n2.1.2 Emerging Production Technologies and Their Industrial Potential\n³¬Éù¸¨ÖúÌáÈ¡£¨UAE£©¡¢¸ß¾²Ë®Ñ¹£¨HHP£©¡¢Âö³åµç³¡£¨PEF£©¡¢Å·Ä·¼ÓÈÈ¡¢Î¢²¨ºÍÑÇÁÙ½çË®µÈͨ¹ý¸Ä±äµ°°×½á¹¹±©Â¶Çиîλµã£¬¶à×÷Ϊø½âÔ¤´¦ÀíÌá¸ß²úÂÊ£»µ«´æÔڷǾùÒ»ÐÔ¡¢ÈÈËðÉË¡¢×ʱ¾³É±¾ºÍ¸ßÄܺģ¬Ñ¡ÔñÓ¦»ùÓÚ²úÆ·¶ø·Ç½ö²úÂÊ¡£\n2.2 Isolation, Purification, and Characterization\n2.2.1 Advanced Separation Methodologies\n³¬ÂË£¨UF£©°´·Ö×ÓÁ¿£¨MW£©·Ö¼¶£¬Ð¡ÓÚ3¨C5 kDa×é·Ö³£»îÐԽϸߣ»Ìå»ýÅÅ×èÉ«Æ×£¨SEC£©¡¢Àë×Ó½»»»É«Æ×£¨IEX£©ºÍ·´Ïà¸ßЧҺÏàÉ«Æ×£¨RP-HPLC£©°´´óС¡¢µçºÉ¡¢ÊèË®ÐÔ´¿»¯£¬ÉúÎï²â¶¨Òýµ¼·Ö¼¶£¬´¿»¯¿ÉÕ¼³É±¾70%¡£\n2.2.2 Peptide Identification and Sequencing Techniques\nÒºÏàÉ«Æ×-´®ÁªÖÊÆ×£¨LC-MS/MS£©ÓÃÓÚÈ·¶¨»îÐÔëľ«È·AAÐòÁС£\n2.3 A Multi-Tiered Approach to Bioactivity Validation\n2.3.1 In Silico Prediction\nin silicoÊý¾Ý¿â¡¢·Ö×Ó¶Ô½Ó¡¢·Ö×Ó¶¯Á¦Ñ§¼°È˹¤ÖÇÄÜ£¨AI£©/»úÆ÷ѧϰ£¨ML£©ÓÃÓÚÔ¤²â»îÐԺʹÓÍ·Éè¼Æ¡£\n2.3.2 In Vitro Screening\nACEÒÖÖÆÒÔIC\n50±íʾ£¬¿¹Ñõ»¯ÓÃDPPH×ÔÓÉ»ùÇå³ý¡¢ôÇ×ÔÓÉ»ùÇå³ýºÍÌú»¹Ô¿¹Ñõ»¯ÄÜÁ¦£¨FRAP£©µÈ£¬¼ò»¯Ìåϵ²»ÄÜ´ú±íÈË¡£\n2.3.3 Cellular and In Vivo Models\nCaco-2ºÍRAW264.7ÓÃÓÚÎüÊÕ¡¢»úÖƺͿ¹Ñ×£¬×Ô·¢ÐÔ¸ßѪѹ´óÊó£¨SHRs£©¡¢DrosophilaºÍ°ßÂíÓãÓÃÓÚÌåÄÚ¡£ÌåÍâÊý¾ÝÓëÈËÌåÁÆЧÍѽڣ¬EFSAÒªÇóÈËÌåÊÔÑ顣ת»¯ÊÇÐò¹áËðºÄ£¬Éæ¼°ëÄø½µ½â¡¢PepT1±¥ºÍ¡¢ÎüÊÕͨ·¡¢¸ÎÊ×¹ýºÍÉöÇå³ý£¬ÐèÄ£ÄâÏû»¯¡¢LC-MS/MS¶¨Á¿¡¢Ò©´úºÍ·Ö²ãÊÔÑé¡£\n2.4 Mechanistic Basis of Major Biological Activities\n¿¹Ñõ»¯ëĹ©µç×Ó/Çâ¡¢òüºÏ½ðÊô²¢¼¤»îKeap1¨CNrf2£»¿¹¸ßѪѹëÄÒÖÖÆACE S1/S2¡¢ÉöËØ»ò¸ÄÉÆÄÚƤÐÍÒ»Ñõ»¯µªºÏø£¨eNOS£©/Ò»Ñõ»¯µª£¨NO£©£»¿¹ÌÇÄò²¡ëÄÒÖÖƦÁ-µí·Ûø¡¢¦Á-ÆÏÌÑÌÇÜÕø¡¢¶þëÄ»ùëÄø-IV£¨DPP-IV£©²¢Ó°ÏìGLP-1¡¢PI3K¨CAkt/GLUT4¡¢AMPK£»¿¹·ÊÅÖëĵ÷½ÚAMPK¡¢PPAR¦Ã¡¢SREBP-1cµÈ£»¿¹¾úëĶàΪÑôÀë×ÓÁ½Çײ¢ÆÆ»µÄ¤£»ÃâÒßµ÷½Úëĵ÷½ÚTLR4¨CMyD88/NF-¦ÊB¡¢MAPK¡¢NLRP3ºÍϸ°ûÒò×Ó£»¿¹°©ºÍÉñ¾±£»¤ëÄ×÷ÓÃÓÚĤ¡¢ÏßÁ£Ìå¡¢µòÍö¡¢Éñ¾µÝÖʺͳ¦¨CÄÔÖᣬµ«ÈËÌåÖ¤¾Ý²»×ã¡£\n3 BAP Commercialization\n3.1 Technical Hurdles in Product Formulation\nÖ÷ÒªÕÏ°ÊÇÎȶ¨ÐÔ/ÉúÎïÀûÓöȡ¢¿àζºÍ»ùÖÊÏ໥×÷Óã»ëÄÒ×±»Î¸³¦µÀ£¨GI£©µ°°×øºÍ¼Ó¹¤Ìõ¼þÆÆ»µ¡£\n3.1.1 Oral Absorption, Systemic Stability, and Tissue Distribution\n¶þ/ÈýëĿɾPepT1£¬ÍêÕûëĿɾÅÔϸ°û¡¢¿çϸ°û¡¢ÔØÌå»òÄÚÍÌ¡£Caco-2Ð豨¸æÖÊÁ¿Æ½ºâºÍ´úлÎϵͳ±©Â¶ÊÜëÄø¡¢¸ÎÌáÈ¡ºÍÉöÇå³ýÓ°Ï죬ǿµçºÉ/´óëÄÄÑ¿çѪ¨CÄÔÆÁÕÏ¡£\n3.1.2 Sensory and Matrix Constraints\nÊèˮˮ½âÎïÒ׿ࣻBAPsÓëÖ¬ÖÊ¡¢Ì¼Ë®»¯ºÏÎï¡¢¶à·Ó¸´ºÏ¿É½µµÍÈܽâÐÔ¡¢Îȶ¨ÐԺͻîÐÔ¡£\n3.2 Innovative Formulation and Delivery Strategies\n°ü·â¿É±£»¤ëÄ¡¢ÑÚ¿àºÍ¿ØÖÆÊÍ·Å£»»·»¯»òN/C¶ËÐÞÊÎÔöÇ¿Îȶ¨ÐÔ¡£\n3.2.1 Comparative Nano- and Micro-Delivery Platforms\nÖ¬ÖÊÌå¡¢¹ÌÌåÖ¬ÖÊÄÉÃ×Á££¨SLN£©/ÄÉÃ׽ṹ֬ÖÊÔØÌ壨NLC£©¡¢ÄÉÃ×Èé/Ë«Èé¡¢¾ÛºÏÎïÄÉÃ×Á£¡¢µ°°×/¶àÌÇÔØÌ塢ˮÄý½º/ÄÉÃ×Äý½ººÍÔÓ»¯ÏµÍ³¸÷ÓÐÔغɡ¢Îȶ¨ºÍ·Å´óÏÞÖÆ£»FDA/EFSAÒªÇó¶ÔÔ¼1¨C100 nm²ÄÁÏÖð°¸ÆÀ¹À£¬¹Ø×¢¶¾ÐÔ¡¢»ùÒò¶¾ÐÔºÍ΢ÉúÎïȺ¡£\n3.2.2 Allergenicity and Safety Considerations of BAPs\nø½â²»×Ô¶¯Ïû³ý¹ýÃô·çÏÕ£»ÈéË®½âÎï²ÐÁô¦Â-ÈéÇòµ°°×Ó°ÏìIgE£¬ëÄÐèÔ¼´óÓÚ3 kDa»ò30 AA²ÅÓÕµ¼·Ê´óϸ°ûÍÑ¿ÅÁ££»½¨ÒéÖ¤¾ÝȨÖØ·¨ºÍEFSAÐÂʳƷָÄÏ¡£\n3.3 Manufacturing Scale-Up, Quality Control, and Industrial Implementation\n·Å´ó¸Ä±ä»ìºÏ¡¢´«ÈȺÍø½Ó´¥£»ÖÊÁ¿Ô´ÓÚÉè¼ÆÁ¬½Ó¹¤ÒÕ²ÎÊýÓëË®½â¶È¡¢·Ö×ÓÁ¿·Ö²¼¡¢ÐòÁÐÖ¸ÎÆ¡¢Ð§¼ÛµÈ¹Ø¼üÖÊÁ¿ÊôÐÔ£»·ÅÐÐÐè×·ËÝ¡¢Ö¸ÎÆ¡¢ÉÚ±øëĺÍЧ¼Û¡£¾¼ÃÊÜø¡¢Ä¤ÎÛȾ¡¢ÄܺĺÍÉ«Æ×Ó°Ï죻¹Ì¶¨»¯Ã¸¡¢Á¬Ðø·´Ó¦Æ÷¡¢¼¼Êõ¾¼Ã·ÖÎöºÍÉúÃüÖÜÆÚÆÀ¹ÀÖØÒª¡£\n3.4 Case Studies of Commercial Products\nEvolusºÍCalpisº¬çÓ°±õ£-¸¬°±õ£-¸¬°±ËᣨVPP£©ºÍÒìÁÁ°±õ£-¸¬°±õ£-¸¬°±ËᣨIPP£©£¬ÓÐκͽµÑ¹×÷Ó㻽ºÔëÄÓÃÓÚƤ·ô¡¢¹Ø½ÚºÍ¹Ç¡£ÊýǧÖÖ·¢ÏÖëÄÖнöÉÙÊýÉÌÒµ»¯¡£\n4 Navigating Regulatory Landscape and Health Claims\n4.1 The Global Regulatory Landscape: An Overview\nFDA¡¢EFSA¡¢¼ÓÄôóÎÀÉú²¿¡¢ÈÕ±¾Ìض¨±£½¡ÓÃʳƷ£¨FOSHU£©¡¢ÖйúʳƷҩƷ¼à¶½¹ÜÀí×ܾ֣¨CFDA£©µÈÌåϵ¾ùÒªÇóÇ¿¿Æѧ֤¾Ý£¬ÓÈÆäÈËÌåÊÔÑé¡£\n4.2 FDA (Us) vs. EFSA (Eu)\nÃÀ¹úÎÞ¹¦ÄÜÐÔʳƷÀà±ð£¬GRASΪ°²È«È϶¨£¬½¡¿µÉù³ÆÐè petition£¬²¹³ä¼Á¿É×÷½á¹¹/¹¦ÄÜÉù³Æ£»Å·ÃËRegulation (EC) No. 1924/2006ÒªÇóEFSAÓªÑø¡¢ÐÂʳƷºÍʳƷ¹ýÃôÔר¼Ò×飨NDA£©ÆÀ¹À£¬Ðè¶àÏîËæ»ú°²Î¿¼Á¶ÔÕÕÈËÌåÊÔÑéÒ»ÖÂÖ¤¾Ý¡£PeptiStrong»ñFDA GRASÎÞÒìÒ飬µ°Ä¤½ºÔëÄ»ñEFSA»ý¼«°²È«Òâ¼û¡£\n4.3 Regulatory Pathways in Asia-Pacific Markets\nÈÕ±¾FOSHUÐèÉóÅú£¬»úÄÜÐÔ±íʾʳƷ£¨FFC£©ÓÉÆóÒµ¸ºÔð£»Öйú¹ú¼ÒÊг¡¼à¶½¹ÜÀí×ܾ֣¨SAMR£©×¢²á/±¸°¸£»°ÄÐÂStandard 1.2.7Ò»°ã/¸ß¼¶Éù³ÆºÍÓªÑø·ÖÎöÆÀ·Ö±ê×¼£¨NPSC£©£»º«¹úʳƷҽҩƷ°²È«´¦£¨MFDS£©·¨µäºÍ¸ö±ðÈÏ¿É¡£ºËÐĵµ°¸¿ÉͨÓõ«Ðè±¾µØÊÊÅä¡£\n4.4 Key Hurdles to Regulatory Approval\nÈËÌåÊÔÑéÖ¤¾Ý²»×ãÊÇÊ×ÒªÕÏ°£»Ë®½âÎïÒìÖÊÐèÃ÷È·»îÐԳɷֲ¢±ê×¼»¯£»»¹ÐèÉúÎïÀûÓöȺͻúÖÆÊý¾Ý¡£\n5 Future Prospects and Research Gaps\nAI/ML¿ÉÔ¤²â»îÐÔ¡¢É¸Ñ¡ºÍ´ÓÍ·Éè¼Æ£»ÓªÑø»ùÒò×éѧºÍÓªÑøÒÅ´«Ñ§Íƶ¯¸öÐÔ»¯£¬¿¼ÂÇÒÅ´«¡¢Î¢ÉúÎïºÍ½¡¿µ×´Ì¬¡£ÐèÆ÷¹ÙоƬµÈÔ¤²âÄ£ÐÍ¡¢³¤ÆÚÈËÌåÊÔÑé¡¢µÍ³É±¾·Å´ó¡¢»ùÖÊ¿ØÖƺͼõ¿à²ßÂÔ¡£\n6 Conclusions\nBAPsDZÁ¦´ó£¬µ«´æÔÚÁÙ´²Ç°¨CÁÙ´²Íѽڡ¢GIÎȶ¨ÐԺ͸йÙÕÏ°¡£ÄÉÃ×°ü·âµÈ¿É½â¾ö²¿·ÖÎÊÌ⣬δÀ´ÒÀÀµ¸ßÖÊÁ¿ÁÙ´²Ñо¿¡¢AIÉè¼ÆºÍ¸öÐÔ»¯ÓªÑø¡£","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261002000744696.htm","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 6290 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 6290 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":6290,"summary_length":6172,"usable_text_length":6290,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":6290,"summary_length":6172}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}